Thanks @Uboy,
The current approach by Sarepta to target surrogate endpoints reminded me of the definition of insanity. Its a case of fool me once shame on you but fool me twice shame on me. The FDA could well be thinking that the time has come to stop messing with surrogate endpoints and begin demonstrating patient benefit. Maybe insanity in this case could better be categorised as inanity.
So is there another approach? As you said, adding an ATL1102 combo arm to their SRP-9001 Endeavour program might just help both Sarepta and the FDA with their respective goals.
One point of interest is that dosing has commenced in the ATL1102 toxicology monkey study. This was a pre-requisite of the FDA for ANP to run a clinical trial for longer than 6 months. Could we pass Go and simply run a combination study?
- Forums
- ASX - By Stock
- PER
- For General Information
For General Information, page-1936
-
-
- There are more pages in this discussion • 1,591 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
Add PER (ASX) to my watchlist
|
|||||
Last
8.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.02M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 365000 | 8.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.3¢ | 214000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 365000 | 0.082 |
1 | 25265 | 0.081 |
4 | 100252 | 0.080 |
2 | 212658 | 0.078 |
1 | 108571 | 0.077 |
Price($) | Vol. | No. |
---|---|---|
0.083 | 214000 | 1 |
0.084 | 57142 | 1 |
0.085 | 90800 | 2 |
0.086 | 106100 | 2 |
0.087 | 158719 | 2 |
Last trade - 08.45am 12/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
Day chart unavailable